Summary of Key Information:
Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)
Nature of Filing / Announcement: Standalone and Consolidated Unaudited Financial Results with Limited Review Report and AGM Notice
Audit Opinion:
Clean Review Opinion - No modifications or qualifications. Statutory auditors Suresh Surana & Associates LLP stated: "nothing has come to our attention that causes us to believe that the accompanying statement... contains any material misstatement."
Key Financial Highlights [₹ in Lakh]:
Standalone Results:
Revenue from Operations: ₹13,471 (Q1 FY27) vs ₹11,225 (Q1 FY26) - 20.0% YoY increase
Total Income: ₹14,077 (Q1 FY27) vs ₹11,720 (Q1 FY26)
Net Profit: ₹139 (Q1 FY27) vs ₹(670) (Q1 FY26) - Significant improvement from loss to profit
EPS: ₹0.23 (Q1 FY27) vs ₹(1.09) (Q1 FY26)
Consolidated Results:
Revenue from Operations: ₹19,957 (Q1 FY27) vs ₹16,670 (Q1 FY26) - 19.7% YoY increase
Total Income: ₹20,381 (Q1 FY27) vs ₹17,237 (Q1 FY26)
Net Profit: ₹220 (Q1 FY27) vs ₹396 (Q1 FY26)
EPS: ₹0.38 (Q1 FY27) vs ₹0.66 (Q1 FY26)
Segment-wise Performance [₹ in Lakh]:
Consolidated Segment Revenue:
Vaccines: ₹13,467 (Q1 FY27) vs ₹11,225 (Q1 FY26) - 20.0% YoY growth
Formulations: ₹6,490 (Q1 FY27) vs ₹5,445 (Q1 FY26) - 19.2% YoY growth
Total Segment Revenue: ₹19,957 (Q1 FY27) vs ₹16,670 (Q1 FY26)
Consolidated Segment Results (Profit/Loss before tax):
Vaccines: ₹747 profit (Q1 FY27) vs ₹(425) loss (Q1 FY26) - Significant turnaround
Formulations: ₹(390) loss (Q1 FY27) vs ₹1,081 profit (Q1 FY26) - Deterioration
Total Segment Results: ₹357 profit (Q1 FY27) vs ₹656 profit (Q1 FY26)
Corporate Actions:
42nd Annual General Meeting to be held on Tuesday, September 29, 2026 at 11:30 A.M. through Video Conferencing/Other Audio-Visual Means
Book Closure Dates: September 25, 2026 to September 29, 2026 (both days inclusive) for AGM purposes
Appointment of Mr. Debabrata Deb Nath, Partner of R&D Company Secretaries, as Scrutinizer for e-Voting process
Other Significant Information:
Exceptional Items: Consolidated exceptional income of ₹274 lakh (Q1 FY27) includes income from deferred consideration of ₹274 lakh from sale of domestic pharmaceutical brands of PBPL
Balance deferred consideration of ₹745 lakh (as of March 31, 2026) to be recognized in subsequent periods
Consolidation includes: Panacea Biotec Pharma Limited, Panacea Biotec (International) S.A., Panacea Biotec Germany GmbH, PanEra Biotec Private Limited, Meyten Realtech Private Limited, Adveta Power Private Limited, and Panacea Biotec Inc
Previous period amounts regrouped/reclassified for comparability
Figures rounded off - '0' represents amount less than ₹50,000